⌕
First Trust Heitman Global Prime Real Estate ETF · PRME · Nasdaq
Tenet 18 · Weak
Compare
$3.84−8.35%At closeTenet 18 · Weak
$3.84−0.35 (−8.35%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

First Trust Heitman Global Prime Real Estate ETF (PRME) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PRME's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 12, 2026 · 18:25 ET
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.32 per share a year ago.…

PRME +2.1% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:15 ET
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

PRME +2.1% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 16:01 ET
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 -- -- Receiv…

PRME +2.1% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 21:40 ET
Prime Medicine Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

PRME +2.1% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 16:05 ET
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

PRME +2.1% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 08:00 ET
Prime Medicine to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced …

PRME +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 04:46 ET
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?

Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…

PRME +2.1% todayRead at source ↗
● Zacks Investment ResearchOct 12, 2026 · 13:25 ET
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.…

PRME +2.1% todayRead at source ↗
● Seeking AlphaOct 11, 2026 · 11:54 ET
Leading Indicators For The October Breakout Cycle

Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of …

PRME +2.1% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 08:00 ET
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most…

PRME +2.1% todayRead at source ↗
● BenzingaSep 25, 2026 · 13:56 ET
Prime Medicine Gets FDA Green Light for Gene Editing Study

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application f…

PRME +2.1% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 18:01 ET
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

PRME +2.1% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 08:00 ET
Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced…

PRME +2.1% todayRead at source ↗
● Defense WorldSep 2, 2026 · 04:09 ET
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME

BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional inves…

PRME +2.1% todayRead at source ↗

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA28−0.4%
WDAY4−5.8%
CRWV30.0%

Article counts from the last market-wide feed page, across every symbol we track and not just PRME · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.